Aldara pharmaceuticals

Common Questions and Answers about Aldara pharmaceuticals


Avatar n tn I was prescribed Aldara (imiquimod) to get rid of a few perianal HPV warts since cryotherapy was only making it worse. After only about 2 weeks of usage almost all symptoms of the warts were gone however I now have perianal psoriasis in its place. That is one of the side-effects of imiquimod and it mainly strikes people whom are genetically prone to having psoriasis.
Avatar n tn One quick follow-up, how is it that Condylox is just as effective as Aldara when they attack the warts two different ways, the Aldara inside within the immune system, and the Condylox from the surface of the wart? Also, I have heard a lot of wart sufferers sing the praises of tea tree oil, that it dries up the wart almost immediately and makes the area very dry/irritated, is this just a cosmetic change to the wart?
Avatar n tn I've been to a dermatologist and I got my biopse done, and they told me I have flat warts (on my face), I don't have a big quantity but I can notice that every month a new one comes out. They told me to treat them with a medication called Aldara, but it is very expensive, so I bought a generic medication from India, which is called Imiquad manufactured by Glenmark Pharmaceuticals. I am using it 3x a week. I know the treatment is slow and that I am not going to have fast results at all.
Avatar m tn When you mention "Gileads therapeutic vaccine" did you mean its TollLike7 receptor agonist drug, that is currently in development or do they indeed also have a therapeutic vaccine in development? The TL agonist drug was tested in Woodchucks as presented in Orlando last year and showed very impressive Vl reductions of 3 to 4 logs. I would like to mention that an other TL7 agonist is already approved for skin conditions. Its name is Imiquimod and the brand name.
Avatar m tn May 19, 2012 - Category: Community Events We have assembled leading scientists from San Francisco Bay Area biotechnology companies who will share their experiences and challenges in transforming an idea for a novel therapeutic into a pharmaceutical that is either market ready or close to ready. You will hear speakers from Amgen, Genentech, Bayer HealthCare, Nektar, Gilead, and Rinat (Pfizer).
Avatar f tn IDIX), Merck (NYSE: MRK) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). For now, Gilead is still King of the Hill. The company has an 800-patient trial underway, and it's possible results of that study could be reported at the American Association for the Study of Liver Diseases' annual meeting next month in Boston. If that happens, we might see Gilead apply for FDA approval as soon as the middle of 2014.